First Participant Treated Using NORTHSTAR MEDICAL RADIOISOTOPES’ Electron Accelerator-Produced Copper-67 (CU-67) in CLARITY PHARMACEUTICALS’ Phase I/IIA THERANOSTIC CLINICAL Trial Investigating CU-67 Sartate for Treatment of Neuroblastoma

NorthStar announced that the first patient has been dosed in a clinical trial using NorthStar’s electron accelerator-produced Cu-67. Administration of the therapeutic dose took place as part of an ongoing Phase I/IIA theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma. The event marks a key milestone in the exclusive Cu-67 supply agreement between both companies.

To read more please visit:

First Participant Treated Using NORTHSTAR MEDICAL RADIOISOTOPES’ Electron Accelerator-Produced Copper-67 (CU-67) in CLARITY PHARMACEUTICALS’ Phase I/IIA THERANOSTIC CLINICAL Trial Investigating CU-67 Sartate for Treatment of Neuroblastoma

Source: Northstar